Cellectar Biosciences Inc (CLRB) has disclosed a new risk, in the Accounting & Financial Operations category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cellectar Biosciences Inc. faces heightened risks due to the restatement of its financial statements for 2022 and 2023, as well as interim periods in 2022 and 2023. This restatement has led to unanticipated costs related to accounting and legal fees, alongside potential lawsuits concerning securities offerings and shareholder claims. The company is now vulnerable to legal proceedings that could incur significant liabilities and reputational damage, regardless of their outcomes. Furthermore, it may encounter additional regulatory scrutiny that could adversely impact its operations and financial health.
The average CLRB stock price target is $1.00, implying 233.78% upside potential.
To learn more about Cellectar Biosciences Inc’s risk factors, click here.